Cogent Biosciences Stock (NASDAQ:COGT)
Previous Close
$10.27
52W Range
$3.67 - $12.14
50D Avg
$9.53
200D Avg
$7.50
Market Cap
$1.16B
Avg Vol (3M)
$984.83K
Beta
0.03
Div Yield
-
COGT Company Profile
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ANAB | AnaptysBio, Inc. |
| OLMA | Olema Pharmaceuticals, Inc. |
| SANA | Sana Biotechnology, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| ZNTL | Zentalis Pharmaceuticals, Inc. |
| KALV | KalVista Pharmaceuticals, Inc. |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| LRMR | Larimar Therapeutics, Inc. |
| MGTX | MeiraGTx Holdings plc |
| VTYX | Ventyx Biosciences, Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| MRSN | Mersana Therapeutics, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| KURA | Kura Oncology, Inc. |
| FIXX | Q32 Bio Inc. |
| LIFE | aTyr Pharma, Inc. |
| VRNA | Verona Pharma plc |